
Opinion|Videos|September 10, 2024
Case Study: Diagnosing and Managing BPH in a Male Patient With Urinary Symptoms
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Patient Case Example: A man in his late 60s who presents with the following:
- History of straining to initiate and maintain a urinary stream, a weak and intermittent urinary stream, a sensation of incomplete bladder emptying after urination, and nocturia; absence of hematuria or dysuria.
- Past Medical History:
- No history of urinary tract infections or other urological conditions
- Hypertension (well-controlled with medication)
- Hyperlipidemia
- No previous surgical history
- Physical Examination:
- Digital rectal examination reveals an enlarged, nonnodular prostate (approximately 50 g); no other significant findings.
- Laboratory and Diagnostic Tests: Serum prostate-specific antigen level: 2.5 ng/mL; urinalysis: normal; uroflowmetry: peak flow rate of 8 mL/sec (borderline obstructed); post-void residual urine volume: 120 mL; transrectal ultrasound: prostate volume estimated at 55 g.
- Please describe your approach to diagnosing, treating, and managing this patient.
Advertisement
Related to this article

These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5

